Investment
Pharmaceutical companies and real estate: the rent versus buy decision
Pharmaceutical giants are transforming their real estate strategies. Industry leaders are shifting from traditional property ownership to strategic lease-ownership balancing for financial efficiency and flexibility.
5 min read
Table of Contents
Written by
More from Life Sciences Real Estate
What does €5–10 million buy in European life sciences real estate?
France and Ireland lead the €5–10 million bracket, largely concentrated in point of care and R&D assets across Europe.
4 min read
Reverse conversions: when science facilities find new purpose
Converting former science facilities to new uses offers investors portfolio protection against tenant risk while unlocking new income streams.
3 min read
Why life sciences real estate deserves a strategic place in professional portfolios
Life sciences real estate offers institutional investors resilient returns, portfolio diversification, and alignment with healthcare megatrends.
5 min read